Intramolecular oxa-Michael and Baylis Hillman Strategies towards Sultam Libraries by Knudtson, Christopher Anton
 i 
Intramolecular oxa-Michael and Baylis Hillman  
Strategies towards Sultam Library Production 
 
By 
 
Christopher A Knudtson 
 
Submitted to the Graduate Program in Chemistry and the Graduate Faculty of the 
University of Kansas in partial fulfillment of the requirements for the degree of Master of 
Arts. 
 
_______________________ 
Chairperson Paul R Hanson 
 
_______________________ 
Robert G Carlson 
 
_______________________ 
Rich S Givens 
 
Date Defended: 4/19/11 
 
 
 
 
 
 
 
 
 
 ii 
The Thesis Committee for Christopher A Knudtson 
Certifies that this is approved version of the following thesis: 
 
Intramolecular oxa-Michael and Baylis Hillman  
Strategies towards Sultam Library Production 
 
_______________________ 
Chairperson Paul R Hanson 
 
 
Date Approved: ___________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
Abstract 
The utilization of Baylis-Hillman and oxa-Michael methodologies for the 
synthesis of sultam (cyclic sulfonamides) libraries from chiral non-racemic amino 
alcohols and epoxides is reported. These strategies employ a divergent synthetic approach 
utilizing a central vinyl sulfonamide linchpin and a variety of functional group pairing 
reactions to generate skeletally diverse sultam scaffolds with a variety of functionalizable 
handles. A variety of 5, 6, 7, and 8-member sultams are accessible through these methods 
with excellent diastereoselectivity, yields, and purities. In addition, the oxa-Michael 
protocol has  been utilized in a one-pot protocol for the synthesis of alibrary of 4,4-dioxo-
1,4,5-oxathiazepines. 
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Chapter 1 
High-Throughput Screening and Diversity-Orientated Synthesis 
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1.1 The Demands of High-Throughput Screening  
The current threats to human well-being include many old and new infections, as 
well as an increasing prevalence of chronic diseases. Among these include cardiac 
disease, cancer, obesity, autoimmune disorders, and degenerative diseases due to old age. 
Current medical care must address the challenges in treating these diseases due to their 
prevalence, mortality rate, healthcare costs, and the patient-to-patient therapy 
administration. In addition, healthcare providers are expected to provide a high quality of 
life through non-invasive, easily administered treatments with mild side effects. Although 
traditional treatments remain popular, the high demands placed on healthcare coupled 
with the ever-changing environment of human disease prevention requires the 
development of new chemical entities which better address current and future threats to 
human health. 
Figure 1. Timeline for Drug Discovery 
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While the demand for new therapeutic agents has existed for many years, the 
pathway to drug development is a long and complex process (Figure 1).1 In order to more 
quickly address the demands for new drugs, enabling technologies have been developed 
which seek to improve the process. High-throughput screening is one such enabling 
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technology which allows for the rapid identification of compounds with biological 
activity2. To properly harness this technology, there must be available large collections of 
potentially druggable molecules in order to screen a diverse set of chemical structures. 
Thus synthetic chemists are challenged to produce diverse small molecule libraries to 
address this demand. 
1.2 Chemical Libraries and Diversity-Orientated Synthesis 
The growing demand for diverse small molecule libraries in the development of 
therapeutic agents requires efficient, innovative methodologies to provide access to these 
structurally unique molecules. These synthetic routes must address the challenges of 
rapid library generation including: access to structurally unique molecules, rapid 
production of compounds, adaptable methodologies, consistent library quality in terms of 
high yields and purities, and enabling the probing of previously unexplored chemical 
space. The possible number of synthesizable molecules is estimated to be in the area of 
1060, while the already available synthetic molecules are estimated around 1013,3 leaving 
a vast area unknown (Figure 2).  
Figure 2: Known Chemical Space and Drug Targets 
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Due to the expansive size of unexplored chemical space, biomedical research 
must utilize guided efforts in order to efficiently probe for pharmacologically active 
structures. Thus, library construction requires a focus on novel scaffolds that not only are 
skeletally diverse and possess the capability for diversification, but also have display 
qualities of potentially drug-like molecules. This challenge is met with the utilization of 
diversity-orientated synthesis (DOS). Pharmacutical research has previously followed a 
target-orientated synthesis (TOS) rational, seeking to synthesize known biological 
compounds. Further drug-discovery efforts have in turn focused on producing analogs of 
these targets through functional-oriented synthesis (FOS)4 (Figure 3).  
Figure 3: Methods for Chemical Probing 
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However, in order to explore unknown chemical space, DOS instead uses 
rationally designed molecules based on known biological data to synthesize libraries of 
structurally unique compounds.5 Thus while TOS and FOS are confined to investigating 
known, although potentially active, chemical space, DOS instead seeks to produce 
compounds which differ greatly from the known chemone in order to probe for potential 
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biological activity. Thus, DOS is able to fulfill the demands of high-throughput screening 
as an efficient, divergent synthetic method which enables the production of a variety of 
skeletal core structures from a common precursers. These unique skeletal cores define an 
unknown chemical space and through functionalizing, produce a library capable of 
defining  a wide area of chemical space for bioactive screening (Figure 4). 
Figure 4: Probing Chemical Space  
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of skeletally complex molecules can be constructed from a common linchpin, thus 
making BCP an enabling strategy for DOS library production (Figure 5). To this end, the 
linchpins in this library were so designed that they can utilize orthogonal coupling 
reactions to selectively cyclize into a variety of chemical structures. 
Figure 5: Build/Couple/Pair Approach to Small Molecule Synthesis 
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Key to the build phase are simple, efficient reactions that have been termed 
“click” reaction. Click reaction are characterized as being modular, clean, high-yielding 
reactions that can utilize commercially available starting materials with simple reaction 
conditions and a strong thermodynamic driving force (Figure 6).10 Some of examples of 
well known click reactions include common carbonyl coupling reactions, nucleophilic 
additions, and heteroatom-carbon bond forming. Click reactions are integral components 
of an efficient and reliable route to highly functionalized linchpins in what is termed a 
“Click, click, cyclize” strategy. Key click reactions in the formation of described 
sulfonamide linchpins include the ring opening of an epoxide to generate an amino 
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alcohol, sulfonylization of a primary amine, and the diversification of the secondary 
sulfonamide as well as the final oxa-Michael and Baylis-Hillman cyclization methods. 
Figure 6: Properties of Click Reactions 
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1.4 Developing DOS Methodologies towards Library Production 
Screening for unique molecules requires a set of metrics as well as an extensive 
pool of known molecules to compare against, a task accomplished with computational 
aid.11 The thus termed ‘in silico’ screening is invaluable in its ability to determine which 
molecules represent areas of unexplored space. It is analogous to HTS in that it is a rapid 
assaying technique and therefore works best with a library of potential molecular 
structures. Candidates that show high diversity scores represent area of chemical space 
unpopulated by the chemical database and possible untapped biological properties. By 
developing methods that produce such skeletally diverse compounds, untapped chemical 
space can effectively be ‘mined’ for bioactivity. 
However, the production of unique molecular structures through traditional, linear 
routes is inadequate for the demands of HTS. Therefore, DOS approaches to library 
production often rely on diverging methodologies12, utilizing a forward thinking rational 
to design structurally different molecules accessible through common intermediates. In 
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addition, these diverging routes are characterized by simple, efficient coupling reactions 
which enable easy, rapid construction of molecules, also a hallmark of DOS approaches. 
A methodology that enables access to a variety of chemical structures is devised by 
pairing selected coupling reactions and commercially available starting materials from a 
common toolbox of each (Figure 7). The DOS approach is further expanded through 
rationally designed molecules with variety of functional groups, capable of undergoing 
orthogonal pairings to yield differing chemical structures simply by changing reaction 
conditions. These armed structures, termed linchpins, in combination with the toolbox 
approach to molecular assembly serve as defining aspects for flexible, modular DOS 
methodologies. 
Figure 7: Developing DOS Methodologies 
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1.5 The Potential of Sulfonamides as Library Targets 
 However, simply producing unique molecules is not enough to effectively 
explore the vast number of potentially synthesizable compounds. Therefore, along with in 
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silico screening, a biological rational is required to provide a metric by which potential 
drug candidates can be selected. Commonly this entails the incorporation of an 
established biologically active core structures into the molecular design or constructing 
small molecules which are analogous to  known bioactive structures.  
A well-known bioactive motifs is the sulfonamide (Figure 8). Sulfonamides have 
a history of medicinal applications, dating back to Prontosil in the 1930’s, with over 
5.400 permutations of the structure in known compounds.13 Originally only known as 
antimicrobials, sulfonamides’ pharmacological profile has expanded into their use a wide 
variety of medications. In particular, sulfonamide-containing heterocycles (sultams) have 
been shown to exhibit wide-ranging, potent biological activity14 including: the anti-
inflammatory agents Ampiroxicam,15 MMP-2 inhibitor,16 HIV integrase inhibitor,17 
selective inhibitors of Calpain I,18 the anti-epileptic agent sulthiame,19 (Figure 1) and 
brinzolamide for the treatment of glaucoma.20 
Figure 8: Bioactive Sulfonamides 
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Compounds containing the sulfonamide moiety are promising candidates in drug 
discovery21 due to their similarity to biologically important amides, but being unknown in 
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nature. Furthermore, these drug-like candidates differ in that they are non-hydrolyzable, 
display a tetrahedral geometry, and moreover demonstrate their own unique chemical and 
biological properties (Figure 9)22. Moreover, their cyclic analogues sulfonamides 
(sultams) have also attracted attention recently due to potent biological activity.23 These 
structures are easily accessed through the simple coupling of a sulfonyl chloride and an 
amine, both of which are available in a wide variety, providing easy access to an 
extensive number of possible combinations. Thus, sultams present attractive targets for 
the production of small molecule libraries.  
Figure 9: Sulfonamide vs Amides 
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 The aforementioned broad-spectrum activity of sulfonamides and their related 
analogs has prompted investigation of new methods for their synthesis. Among the 
methods that have recently emerged as powerful methods for the generation of sultams 
derivatives are Pictet-Spengler,3a Friedel-Craft,24 dianion,25 cyclization of aminosulfonyl 
chlorides,26 [3+2] cycloadditions,27 Diels-Alder,28 Heck reaction,29 RCM30 and other 
transition-metal catalyzed reactions.31 The desire to explore new methods of sultam 
formation prompted investigation into the reaction profile of the vinyl sulfonamide 
moiety.32 
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Figure 10: A DOS Linchpin Approach to Sultam Synthesis 
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 The oxa-Michael31 and Baylis-Hillman32 reactions are simple, yet powerful 
methods for bond formation.  Although discovered a long time ago35, the intramolecular 
version of the Michael reaction has seen a renaissance and has been extensively utilized 
in natural product synthesis for over two decades. Although the Michael accepting ability 
of vinyl sulfones is well documented,36 their vinyl sulfonamide counterparts have 
assumed a far less prominent role as viable Michael acceptors.37 In contrast, the 
intramolecular version of the Baylis-Hillman reaction has only recently gained favor, 
where elegant work in this area has elevated the status of this variant.38 Although the 
Michael accepting ability of vinyl sulfones is well documented, their vinyl sulfonamide 
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counterparts have assumed a far less prominent role as viable Michael acceptors. Herein 
we report the first examples of intramolecular oxa-Michael and Baylis-Hillman reactions 
on vinyl sulfonamides to afford an array of novel five, six, seven and eight-membered 
sultam derivatives in good to excellent yields. Good to excellent levels of 
diastereoselectivity were achieved ultimately yielding a number of interesting sultam 
scaffolds for library production. 
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Chapter 2 
Development of Oxa-Michael and Baylis-Hillman Methodologies 
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2.1 Rationale For Sultam Library Design 
In order to produce libraries of compounds sufficient to meet the demands of 
HTS, a DOS approach to sultam synthesis was developed. To this end the 
aforementioned “build, couple, pair”  strategy was utilized as a core principle in the 
methodology design. A strategy for DOS sultam production focused on the use of easily 
accessed acyclic sulfonamide linchpins and orthogonal coupling pathways to access a 
variety of unique structures (Figure 1). 
Figure 1: Functional Group Pairing on a Sulfonamide Linchpin 
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The vinyl sulfonamide moiety is an attractive lynchpin component as it exhibits 
unique chemical properties and special reactivities (Figure 2). The conjugated olefin has 
both nucleophilic and electrophilic components due to the electron-withdrawing nature of 
the sulfonyl group, enabling the use of a variety of novel cyclization methods through 
generally mild conditions.1 In addition, the electronegativity of the oxygen in the sulfonyl 
group results in an acidic –NH, demonstrating a lower pKa than corresponding amides, 
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and making sulfonamide alkylation relatively less demanding2. The sulfur’s size in 
combination with the longer C-S bond length is expected cause angle compressing of the 
sulfonamide’s functionalized arms, allowing ring closures usually deemed inaccessible 
according to Baldwin’s rules3. Furthermore, the gem-dioxa groups are also believed to 
restrict rotation around the sulfur atom, affecting reactions in a manner similar to the 
Thorpe-Ingold effect,4 as seen in ring-closing metathesis of sulfonamides.5 Thus 
sulfonamide cyclizations are expected to proceed at increased reaction rates and milder 
conditions due to functional groups being brought closer together.  
Figure 2: Properties of Vinyl Sulfonamides 
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This wide range of chemical properties allows this moiety participate in a variety 
of coupling reactions. In addition, there is a wide availability of building blocks able to 
incorporate diversity elements into the sulfonamide, including benzyl bromides, amines, 
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and benzoyl chlorides. Literature gives evidence of the wide-ranging reaction profile of 
sulfonamides in Diels-Alder6,  Heck7, indium-initiated radical addition, and [3 + 2] 
cycloaddition reactions8. Further work has shown their feasibility in ring-closing 
metathesis (RCM)9, intramolecular oxa-Michael, and Baylis-Hillman10 cyclizations to 
generate sultams. This makes investigation into sulfonamide library production a 
particularity fruitful endeavor, with a large number of possible synthetic routes to explore 
(Figure 3). 
Figure 3: Sultams Accessible from the Vinyl Sulfonamide Linchpin 
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The first BCP strategy sought to make use of the excellent Michael-acceptor 
properties of the vinyl sulfonamide for an intramolecular cyclization. To this end, it was 
envisioned that a deprotonated hydroxy group would be ideal, thus allowing for the 
construction of the sultam from commercially available amino alcohols. While previous 
oxa-Michael reactions have demonstrated issues with selectivity and reactivity11, it was 
thought that the intramolecular nature of the cyclization combined with the reactivity of 
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the activated olefin would overcome this. In addition, a second strategy would make use 
of the presence of a terminal hydroxy group in the oxidation to an aldehyde, followed by 
a Baylis-Hillman cyclization to the nucleophilic carbon of the vinyl sulfonamide. This 
would form a highly functionalized sultam conserving both the vinyl sulfonamide and 
hydroxy groups, and enabling further diversification steps. Further cyclization methods 
were also envisioned with this linchpin, including ring-closing metathesis (RCM), but not 
explored at this time (Figure 4). 
Figure 4: Oxa-Michael and Baylis-Hillman Pathways 
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The amino alcohol represents a highly desirable starting material. They are 
available in a wide variety of forms, with different substitutions, chirality, and chain 
lengths (Figure 5).12 This allows for the development of differing skeletal structures from 
the same methodology simply by changing a single component of the synthesis. 
Furthermore, the presence of a stereogenic center in many amino alcohols allows for the 
easy incorporation of chirality in a molecule. Thus the amino alcohol moiety offers 
access to a variety of chiral 7- and 8-member oxa-Michael products through the simple 
incorporation of a commercially available building block. In addition, the amino alcohol 
moiety is present in a number of natural products, including amino sugars, nucleosides, 
and nucleotides.13 
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Figure 5: Commercially Available Amino Alcohols 
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In order to evaluate how unique the proposed compounds are compared to other 
known structures, they were submitted for in silico screening. The diversity model 
utilized at KU utilizes an algorithm to compare structures to known molecules within the 
database. The algorithm utilizes 5 properties called diversity elements (high positive 
charge, high negative charge, high polizerability, low polizerability, and number of H-
bonding atoms) scaled in 10 degree increments to compare structures, thus creating a 
matrix of 10^5 or 100,000 cells14 (Figure 6). Proposed molecules are assigned to cells 
based on how the algorithm utilizes these diversity elements to interpet their structure. 
Compound diversity scores are calculated based on the number of known compounds 
populating their assigned cells relative to the average cell population, which is weighted 
relative to the compound population of individual cells rather than a straight average.  
Figure 6: Calculating Diversity Scores 
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Therefore in a matrix with an average cell population of 98.1, a compound in a 
cell with a population of 98 is assigned a diversity score of 1, as its diversity is relatively 
equal to the average population of the matrix. A compound in a cell with half the average 
population would have a score of 0.5, being twice as unique as the average compound, 
just as a compound in a cell with twice the average population would be half as diverse, 
receiving a score of 2. Ideally, compounds screened as possible candidates for DOS 
should have a diversity score of 0.5 or less to ensure compound libraries represent less 
populated areas chemical space and are relatively dissimilar to klnown chemical 
compounds. The submitted structures showed relatively low diversity scores, (Figure 7) 
indicating good target structures for DOS. 
Figure 7: Diversity Scores of Selected Sultams 
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2.2 Oxa-Michael Strategies for Sultam Synthesis 
In order to ensure that the sulfonylation would chemoselectivly target the amine 
under reaction conditions, the hydroxy group would have to be protected. For this, a silyl 
ether was chosen due to the mild conditions of protection and deprotection,15 and its 
selectivity for the alcohol over the amine16. Furthermore the following reaction steps and 
workup were devoid of conditions that would deprotect the silyl ether. The protection 
proceeded easily by the addition of a slight excess of TBSCl to a stirring solution of the 
amino alcohol and triethylamine in DCM with a catalytic amount of imidazole. The 
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reaction was allowed to stir overnight, during which it formed a thick slurry from 
precipitated salts. Workup involved extraction 3x with DCM, a brine wash, addition of 
sodium sulfate to remove excess moisture, filtration and rotary evaporation. This workup 
would be followed for all procedures unless otherwise noted. Following workup, the 
TBS-protected amino alcohols were isolated as a viscous, off-white, semi-crystalline 
liquid. 
The assembly of the vinyl sulfonamide linchpins began with the reaction of 2-
chloroethanesulfonyl chloride with various TBS-protected amino alcohols 1. The sulfonyl 
chloride was added dropwise to a stirring solution of the TBS-protected alcohol and 
triethylamine in DCM. Due to the extremely exothermic nature of the sulfonylation, it 
was performed in an ice bath with the sulfonyl chloride added slowly to the reaction. A 
yellow color was noted during the addition of the sulfonyl chloride, most likely from the 
presence of the free sulfonamide base. The reaction proceeded rapidly and was complete 
in less than 2 hrs. Workup and isolation produced the products as yellow oils. 
Diversification of the vinyl sulfonamides 2 proceeded through either benzylation 
or allylation methodologies. An excess (1.5 eq) of the diversification reagents were added 
in solution of the vinyl sulfonamide in acetonitrile with K2CO3 to maintain a basic 
environment.17 The reaction mixture was refluxed at 80 ºC until complete (usually about 
4 hrs). The increased nucleophilicity of the nitrogen allowed for smooth transformation, 
with all of the starting material converted to the vinyl sulfonamide linchpin 3. 
It was anticipated that following TBAF-initiated TBS-deprotection of the alcohol, 
a NaH-initiated Michael addition would have to be performed. However, it was found 
that TBAF addition led to the formation of oxygen anion, which subsequently underwent 
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oxa-Michael reactions in a single step to afford the unique seven-membered sultams 4 via 
7-endo Trig ring closure pathways in excellent yields (Scheme 1). Thus, the reaction 
proceeded by the simple addition of 1 eq. of TBAF in THF to a stirring solution of the 
sulfonamide linchpin in THF. The reaction was complete in under 30 min, yielding 
thiooxaazepines in good yields and purities. The final products were purified by flash 
chromatography and Mass-Directed Fractionation (MDF) process and submitted for 
biological screening. 
Scheme 1: Oxa-Michael Synthesis of Sultams via 7-endo-Trig Ring Closure Pathway 
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The high yields, mild reaction conditions, and little need for chromatography 
between steps led to interest in developing this procedure for a one-pot protocol. To 
achieve this, the TBS-protected amino alcohols were added to a sealed reaction tube and 
submitted to sulfonylation conditions. Following completion, the reaction solution was 
divided into separate reaction tubes for diversification. To each tube was added a separate 
diversification reagent and all tubes underwent the benzylation reaction conditions. Upon 
complete conversion, TBAF was added to the stirring reaction to initiate oxa-Michael 
cyclization. The crude reaction mixture was purified using chromatography to yield the 
products in good yields over 3 steps. Using this one-pot protocol it was possible to 
synthesize 5 compounds a day from a common starting material. 
While the commercially available amino alcohols offer a wide variety of 
diversification, the synthesis of designed amino alcohols would expand the number of 
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compounds accessible through this synthetic route and possibly enable the incorporation 
of additional functionalities not available through commercial building blocks. To this 
end, the opening of trityl glycidyl ethers 5 with primary amines was investigated as a 
method for the production of amino alcohols (Scheme 2). In a minimum amount of 
methanol as a solvent, the amine, ether, and a catalytic amount of Zn(ClO4)2•H2O was 
allowed to stir overnight. The yellowish oil was immediately subjected to previously 
described TBS protection procedure to yield the double-protected amino alcohols 6 in 
excellent yields and purities. The synthesized amino alcohols were submitted to the oxa-
Michael methodology, followed by a final deprotection of the trityl group to yield the 
thiaoxaazepines 8 in moderate yields. 
Scheme 2: Epoxide Ring Opening in Sultam Synthesis 
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2.3 Baylis-Hillman Strategies for Sultam Synthesis 
The Baylis-Hillman (BH) reaction is a powerful C-C bond-forming reaction, 
enabling the production of heterocycles and other cyclic structures containing allylic 
alcohol functional groups. It is catalyzed by the nucleophilic addition of an amine to an 
election deficient alkene, forming a zwitterion which then attacks an electrophilic 
aldehyde, finally eliminating the amine catalyst to form the allylic alcohol. Therefore the 
same electron-deficient nature of the vinyl sulfonamides that makes them excellent 
Michael acceptors and also makes the moiety suitable for BH cyclization.  
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The investigation of methodologies for the formation of the Baylis-Hillman 
precursor has led to the development of two differing synthetic routes toward BH-
cyclized sultams. The first route makes use of a chemoselective oxidation of the terminal 
olefin to generate the corresponding aldehyde in the presence of the vinyl sulfonamide. 
The second pathway took the previously described vinyl sulfonamide lynchpin through a 
two-step deprotection and oxidation methodology to generate the reactive aldehyde. Both 
routes made use of the same BH cyclization conditions to synthesize highly 
functionalized 5 and 6-membered sultam derivatives. 
The first methodology involved a key oxidation step that chemoselectivly targeted 
a terminal alkene over the vinyl sulfonamide to produce precursors for BH cyclizations 
(Scheme 3). To this extent, ozonolysis was selected, as it is a well-established method for 
the conversion of olefins to aldehydes. It was predicted that the electron-deficient vinyl 
sulfonamide would be resistant to ozonolysis, allowing for chemoselective oxidation of 
the terminal olefin.  
Scheme 3: Chemoselective Ozonolysis/Baylis-Hillman pathway  
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The synthesis began using primary amines 9 for the construction of the vinyl 
sulfonamides 10 from via previously described methods. Instead of benzylation, all 
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compounds were allylated to yield linchpins 11 with terminal olefins. Selective oxidation 
of the vinyl sulfonamides by ozonolysis proceeded by bubbling ozone through a solution 
of the sulfonamide in methyl sulfide spiked with Sudan III until the indicator’s color 
faded. The vinyl sulfonamide aldehydes 12 were isolated in moderate yields and high 
purity. Intramolecular Baylis-Hillman proceeded rapidly to produce the 5-member 
cyclized products 13 in excellent yields. It was notable that unlike most intermolecular 
Baylis-Hillman reactions, which normally take a long time to complete, this Baylis-
Hillman reaction proceeds in 2 to 4 h. 
This chemoselective oxidation/Baylis-Hillman protocol was further extended to a 
chiral starting material (Scheme 4). The synthesis began with (S)-glycidyl ether 14 
whereby treatment with trimethyl sulfonium iodide and butyl lithium at low temperature 
(-30 ºC) generated chiral allyl alcohol 15.28 Following Mitsunobu reaction of 15 with 
phthalimide and hydrazine,29 chiral allyl amine 16 was obtained in 61% yield over 3 
steps. Sulfonylation to 17, followed by benzylation afforded 18, which underwent 
chemoselective oxidation to generate aldehyde 19. Baylis-Hillman cyclization of 19 
afforded sultam 20 as an inseparable 4:1 diastereomer mixture in 86% yield. 
Scheme 4: Chemoselective Oxidation of Chiral Allyl Vinyl Sulfonamide to Make Baylis-
Hillman Sultam Derivatives. 
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An alternative to the chemoselective oxidation of vinyl sulfonamides towards 
Baylis-Hillman precursors is the use of TBS-protected amino alcohols as starting 
materials. Using the same procedure as with the OM method, vinyl lynchpins were 
prepared as precursors for the BH cyclization. It was found aqueous HCl promotes TBS-
deprotection without initiating the intramolecular oxa-Michael reaction, resulting in the 
formation of corresponding alcohol. This pathway is more attractive than the former 
chemoselective oxidation/Baylis-Hillman pathway due the ease of production from 
commercially available amino alcohols, the milder reaction conditions, and the utilization 
of a common synthetic route with the OM method, demonstrating the vinyl sulfonamide 
linchpin as a single molecular structure armed for differing intramolecular cyclization 
methods. 
Investigation of the second pathway began with sulfonylation of chiral amino alcohols 
21 (Table 3) to afford vinyl sulfonamides 22. Following benzylation, vinyl sulfonamides 
23 were obtained in excellent yields. Removal of TBS-protection by acid (10 mol% HCl) 
generated vinyl sulfonamide alcohols, which underwent oxidation by Dess-Martin 
periodate to yield vinyl sulfonamide aldehydes 30. Baylis-Hillman reactions of 24 
produced five-membered sultams 25/26 in excellent yields with moderate to good 
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diastereoselectivity. Other organocatalysts such as brucine, quinine and quinidine were 
also used (Table 1) but proved less efficient than DABCO, resulting low yield and 
moderate selectivity. 
 
 
 
 
 
 
Scheme 5: Intramolecular Baylis-Hillman Protocol via Chiral Amino Alcohols 
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Table 1: Catalysts for Baylis-Hillman Cyclization 
Entry Catalyst 
Amino 
alcohol 
Product 
Yield 
(%)a 
dr 
ratio 
1 DABCO 
NH2TBSO
 
N
S
OO
HO
33a
 
69 1.7:1 
 35 
2 DABCO 
NH2TBSO
i-Bu  33b
N
S
OO
HO i-Bu  
67 3.2:1 
3 DABCO 
NH2TBSO
i-Bu  
33c
N
S
OO
HO i-Bu
Br  
71 1.6:1 
4 DABCO 
NH2TBSO
Bn  33d
N
S
OO
HO Bn  
69 3.3:1 
5 DABCO 
NH2TBSO
Bn  
33e
N
S
OO
HO Bn  
71 9.0:1 
6 Brucine 
NH2TBSO
Bn  
33e
N
S
OO
HO Bn  
46 
(72 
h) 
10:1 
7 Quinine 
NH2TBSO
Bn  
33e
N
S
OO
HO Bn  
45 
(72 
h) 
9.2:1 
8 Quinidine 
NH2TBSO
Bn  
33e
N
S
OO
HO Bn  
42 
(72 
h) 
8.5:1 
a Isolated yields from 23 to 25/26. 
Further investigation of the method to generate larger sultam rings utilized TBS-
protected 3-amino-1-propanol 27 as a starting material. Sulfonylation with 2-
chloroethanesulfonyl chloride to generate 28, followed by allylation yielded vinyl 
sulfonamide 29 (Scheme 6). From here, the vinyl sulfonamide could either undergo 
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TBAF deprotection to the 8-membered oxa-Michael sultam 30 or acidic TBS-
deprotection followed by the Dess-Martin oxidation to aldehyde 31, which readily 
underwent Baylis-Hillman cyclization to afford 6-membered sultam 32 in 68% yield over 
3 steps. However, attempts at producing corresponding 7-member sultams proved 
unsuccessful. 
Scheme 6: Intramolecular Baylis-Hillman Protocol for Six-Membered Sultam Synthesis 
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The combination of the oxa-Micahel and Baylis Hillman approaches into a single, 
divergent methodology was investigated utilizing chiral amino alcohol starting materials, 
synthesized from glycidyl trityl ethers 31 (Scheme 10). The epoxide ring was opened by 
iso-butyl amine,30 to afford the amino alcohols 32 followed by subsequent TBS-protection 
to yield the silyl-protected amino alcohol 33. Sulfonylation of 33 with 2-
chloroethanesulfonyl chloride afforded vinyl sulfonamide linchpin 34. From here, the 
Baylis-Hillman pathway was initiated by use of a selective, orthogonal deprotection of 
trityl ether 34 affording vinyl sulfonamide 35. The resulting alcohol 35 was oxidized to 
aldehyde 36 using Dess-Martin periodinate.  Treatment of 36 with DABCO afforded the 
sultam 37 in excellent yield with >95:5 diastereoselectivity. Intramolecular oxa-Michael 
pathways were then pursued through selective deprotection of the alcohols. The first oxa-
 37 
Michael cyclization utilized TBAF to selectively deprotect and cyclize the TBS-
deprotection alcohol to afford 7-member sultams 38. An alternative utilized the 
terminally deprotected alcohol 35, but through a NaH-initiated oxa-Michael cyclization 
of 35 to afford an 8-membered sultam 39. Both reactions proceeded quickly and provided 
sultams in excellent yields. 
Scheme 10.  Functional group pairing through oxa-Michael and Baylis-Hillman 
Cyclizations 
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2.4 Future Work 
 The vinyl sulfonamide moiety continues to present potential for the application of 
new cyclization methods to access sultam compounds. Continued work by Qin Zang in 
the Hanson group has given evidence for thio-Michael, aza-Michael, and bis-aza-Michael 
methodologies, as well as continued exploration of the oxa-Michael pathways (Scheme 
11). In addition, the highly-functionalized Baylis-Hillman adducts are an attractive 
structure for diversification that has yet to be explored. Further investigation into 
cyclization methods, possible building blocks, and orthogonal reactions are expected to 
expand the reaction profile and compounds accessible through this moiety. 
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Scheme 11: Further Work in Hetero-Michael Pathways 
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2.5 Conclusions 
In summary, two protocols involving intramolecular oxa-Michael and Baylis-Hillman 
reactions to generate 5, 6, 7 and 8-membered sultam derivatives have been reported. 
Empirical evidence validating 8-endo Trig cyclization pathway in oxa-Michael reactions 
has been presented which enriched Baldwin rules for ring closure. The oxa-Michael 
method has been shown to be a rapids production method, easily implemented in a one-
pot procedure. For Baylis-Hillman protocol, two pathways were demonstrated: (I) a 
chemoselective oxidation/Baylis-Hillman and (II) use of a vinyl sulfonamide alcohol. 
Both pathways were completed within short order and occurred with good to excellent 
yields. In addition, good to excellent levels of diastereoselectivity were achieved. 
Overall, these two reactions can be conveniently combined into one synthetic route to 
produce skeletally diverse scaffolds from a single precursor in excellent yields.  Finally, 
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these methods are highly amenable to library generation and current efforts are currently 
engaged in this endeavor, with additional potential for expanding the scope of these 
methodologies. Libraries are currently in progress and some of sultam the compounds are 
currently undergoing biological screening through the NIH Molecular Library Screening 
Network (NIH-MLSCN).  
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Chapter 3 
Sultam Library Information 
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3.1 Synthesis of an Oxa-Michael Library of Sultams 
The 95-member oxa-Michael library was planned as an extension of previously 
reported syntheses in a library format. Previous results had shown that the reaction 
conditions were well tolerated by all substrates and intermediates and yielded products 
with a minimal amount of purification, leading to the development of a one-pot 
methodology. Due to the ease and speed of production in this one-pot method, the library 
was to be carried out in a one-pot fashion in parallel reaction vessels. Two points of 
diversity were incorporated into the basic framework, rising from the amino alcohol 
starting materials (R1) as well as a variety of alkylating and benzylating agents (R2). 
Commercially available, enantiopure amino alcohols were also used to set both ring size 
and chirality of the resulting thiooxaazepines (Scheme 1). 
Scheme 1:  Intramolecular oxa-Michael Reaction to Generate Sultams 
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The syntheses of the sultam library was carried out in parallel synthetic tubes. 
TBSCl (1.05 equiv.) dissolved in CH2Cl2 was added respectively to parallel tubes 
containing a solution of an amino alcohol (1.0 equiv.), triethylamine (3.0 equiv.) and 
small amount of DMAP (0.05 equiv.) in CH2Cl2. After addition, the reactions were 
stirred overnight and checked by TLC for completion. The reactions were cooled to 0 ºC 
and additional triethylamine (3.0 equiv.) was added along with 2-chloroethanesulfonyl 
chloride (1.05 equiv.). After 2 h, the crude reation mixtures were washed with brine and 
evaporated under a sample concentrator to yield crude vinyl sulfonamides. The resultant 
crude vinyl sulfonamides were re-dissolved in calculated amount of acetonitrile and 
distributed into parallel tubes for diversification. To each tube, two equivalents of 
potassium carbonate were added, followed by the addition of alkylating or benzylating 
agents (1.05 equiv.). All reaction tubes were simultaneously heated at 80 ºC for 5 h, then 
cooled down to rt. Solid potassium carbonate was removed by filtration. Acetonitrile 
solvent in filtrate was evaporated from the reaction vessels, and the resulting  crude vinyl 
sulfonamide was directly submitted to oxa-Michael reaction conditions.  1 M TBAF in 
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THF solution was added into alkylated vinyl sulfonamide solution in THF in parallel 
tubes to initiated the intramolecular oxa-Michael cyclization, after 2 h, saturated 
ammonium chloride solution was added, followed by the addition of CH2Cl2 to extract 
organic layer. The combined organic layers were dried over MgSO4, and evaporated via a 
sample concentrator. The final products (seven and eight-membered sultams) were finally 
purified by Mass-Directed Fractionation (MDF). 
Diversification components were chosen from commercially available amino 
acids and alkylating agents. The goal of building block selection was to take advantage of 
the wide variety of available materials in producing a diverse array of sultams. The amino 
acids had both cyclic and acyclic structures in a variety of conformations. This aims to 
produce sultams with a multitude of 3-dimensional shapes in order to maximize the 
number of possibly biologically relevant interactions explored in the screening process. 
In a similar line of thinking, the alkylating agents chosen made use of the variety of 
substituted benzyl bromides, which not only were excellent alkylating agents, but had 
both electron-withdrawing and electron-donating substituents in differing positions. The 
building blocks of amino alcohols and alkylating agents for library production are shown 
in Scheme 2. 
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Scheme 2. Building Blocks for Sultam Synthesis 
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The purities of crude products and final products were analyzed by HPLC. Most 
crude products were isolated with purities ranging from 80~90%, with final purities 
ranging from 95-100% after MDF (Scheme 4), all these compounds have been submitted 
for high throughput screening for biological testing. This method afforded not only 7 and 
8-membered sultams, but also generated monocyclic, bi-cyclic and tri-cyclic sultams with 
different stereogenic centers. 
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Table 1: A 95-Member Sultam Library 
O
N
S
OO
CH3
Ph
R
 
Entry R2 Sult
am 
Yield 
% 
Purity 
% 
1 -C6H5 1a 37.4 100 
2 2-Br-
C6H4 
1b 18.5 100 
3 4-CH3-
C6H4 
1c 18.7 100 
4 4-F-C6H4 1d 27 100 
5 2-F-C6H4 1e 11.5 100 
6 3-Cl-
C6H4 
1f 31.4 100 
7 3-F3C-
C6H4 
1g 29.9 96.2 
8 2-CH3-
C6H4 
1i 17.4 100 
 
 
 
 
 
O
N
S
O
O
R
 
Entry R2 
Sultam 
Yield 
% 
Purity 
% 
9 -C6H5 2a 39 100 
10 2-Br-
C6H4 
2b 46 100 
11 4-CH3-
C6H4 
2c 37 100 
12 4-F-
C6H4 
2d 36.6 100 
13 2-F-
C6H4 
2e 47.2 100 
14 3-Cl-
C6H4 
2f 50.9 100 
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15 3-F3C-
C6H4 
2g 36.3 100 
16 2-CH3-
C6H4 
2i 46.5 100 
 
O
N
S
OO
R
 
Entry R2 
Sultam 
Yield 
% 
Purity 
% 
17 -C6H5 3a 71.4 99.9 
18 2-Br-
C6H4 
3b 52.7 99.9 
19 4-CH3-
C6H4 
3c 58.5 100 
20 4-F-
C6H4 
3d 57.9 100 
21 2-F-
C6H4 
3e 74.1 100 
22 3-Cl-
C6H4 
3f 78.8 100 
23 3-F3C-
C6H4 
3g 75.9 100 
24 4-Cl-
C6H4 
3h 57 100 
25 2-CH3-
C6H4 
3i 68.6 100 
 
N
S
O
O
O
R
 
Entry R1 Sult
am 
Yield 
% 
Purity 
% 
30 -C6H5 4a 49 99.6 
31 2-Br-C6H4 4b 60.5 100 
32 4-CH3-C6H4 4c 54.5 100 
33 4-F-C6H4 4d 60.0 99 
34 2-F-C6H4 4e 51.7 100 
35 3-Cl-C6H4 4f 69.4 99 
 48 
36 3-F3C-C6H4 4g 61.2 100 
37 4-Cl-C6H4 4h 52.4 95.9 
38 2-CH3-C6H4 4i 59.5 100 
 
O
N
S
OO
R1
R2
 
Entry R1 R2 Sultam Yield % Purity % 
39 
 
Bn 5a 62.4 99.8 
40 
 
2-BrBn 5b 69.9 99.9 
41 
 
4-CH3Bn 5c 51.5 100 
42 
 
4-FBn 5d 63.5 100 
43 
 
2-FBn 5e 66.3 100 
44 
 
3-ClBn 5f 62.9 100 
45 
 
3-F3CBn 5g 83.6 100 
46 
 
4-ClBn 5h 62.4 99.6 
 49 
47 Pro NA 6 55.3 97.8 
48 Et Bn 7a 71.6 100 
49 Et 2-BrBn 7b 71.6 100 
50 Et 4-CH3Bn 7c 35.1 99.6 
51 Et 4-FBn 7d 66.1 100 
52 Et 2-FBn 7e 75 100 
53 Et 3-ClBn 7f 78.6 100 
54 Et 3-F3CBn 7g 81.8 100 
55 Et 4-ClBn 7h 57.9 100 
56 Et 2-MeBn 7i 75 99.7 
57 Bn Bn 8a 80.4 100 
58 Bn 2-BrBn 8b 88.1 100 
59 Bn 4-CH3Bn 8c 76.8 99.8 
60 Bn 4-FBn 8d 87.5 100 
 50 
61 Bn 2-FBn 8e 96.1 99.2 
62 Bn 3-ClBn 8f 100 100 
63 Bn 3-F3CBn 8g 100 100 
64 Bn 4-ClBn 8h 87.6 100 
65 Bn 2-MeBn 8i 88.3 100 
66 Bn propargyl 8j 92.9 100 
67 Bn vinyl 8k 95.5 99.2 
68 Bn 2,4-ClBn 8l 100 98.2 
69 Bn 3,4-ClBn 8m 100 100 
70 Bn 3-FBn 8n 94.5 100 
71 Bn 3-NO2Bn 8o 100 99.5 
72 t-Bu Bn 9a 100 100 
73 t-Bu 2-BrBn 9b 96.4 100 
74 t-Bu 4-CH3Bn 9c 95.2 100 
 51 
75 t-Bu 4-FBn 9d 96.5 100 
76 t-Bu 2-FBn 9e 89.7 100 
77 t-Bu 3-ClBn 9f 100 100 
78 t-Bu 3-F3CBn 9g 100 100 
79 t-Bu 4-ClBn 9h 96.5 100 
80 t-Bu 2-MeBn 9i 92.5 99.8 
81 t-Bu propargyl 9j 91.3 100 
82 t-Bu vinyl 9k 100 100 
83 t-Bu 2,4-ClBn 9l 100 99.3 
84 t-Bu 3,4-ClBn 9m 100 97.5 
85 t-Bu 3-FBn 9n 95.3 100 
86 t-Bu 3-NO2Bn 9o 99.5 100 
87 t-Bu 3-MeBn 9p 95.6 100 
88 t-Bu 4-OMeBn 9q 100 79.8 
 52 
89 Ph Bn 11a 84.0 99.3 
90 Ph 4-FBn 11d 81.0 100 
91 Ph 2-FBn 11e 78.0 100 
92 Ph 3,4-ClBn 11m 91.0 92.0 
93 Ph 3-FBn 11n 77.0 92.0 
94 Bu 4-BrBn 12r 88.0 95.6 
95 i-Bu 4-BrBn 13r 78.1 87.0 
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Figure 1: Bioactivity of Selected Submitted Compounds 
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3.2 Baylis-Hillman Products 
 
A small sample library of substituted Baylis-Hillman products was also produced. 
Less of these compounds were produced than the Oxa-Michael sultams due to the relative 
ease of the Oxa-Michael methodology. Also, due to the highly substituted nature of the 5-
member sultams, they are better suited as scaffolds for functionalization than endproducts 
in themselves. With this in mind a small library was submitted for biological testing to 
determine if the core structures had bioactive potential. Thus far no positive results have 
been found. 
Scheme 3: Synthesis of Baylis-Hillman Dervied Sultams 
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Table 2: A Sample Library of Baylis-Hillman Products 
S
N
OO
HO
R
 
Entry 
 
R 
Yield % Purity % 
10a iPr 37.4 100 
10b 4-OMe-Ph 18.5 100 
10c Bn 27 100 
10d CycHex 11.5 100 
10e tBu 31.4 100 
10f propargyl 29.9 96.2 
10g CH2COOMe 17.4 100 
 
Conclusion: 
 A 95-sultam library of sultams using intramolecular oxa-Michael reaction of vinyl 
sulfonamides was accomplished. All reactions involved were “click-type” reactions. The 
4-step reaction sequence proceeded without flash chromatography of reaction 
intermediates; easy work-up and preparative HPLC/MS purification provided high yield 
and purity library products. Of the compounds submitted for screening, several have 
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displayed bioactivity, including a 12 µM inhibitor of Pseudomonas Aeruginosa PvdQ 
acylase. A small library of Baylis-Hillman products were synthesized and submitted, but 
have not yet demonstrated activity in the assays. All the sultams reported herein have 
been submitted to NIH biological outreach partners for biological screening through the 
NIH Molecular Library Screening Network (NIH-MLSCN). 
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Chapter 4 
Experimental Procedures and Data 
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3.1 General Methods 
All air and moisture sensitive reactions were carried out in flame-dried glassware 
under argon atmosphere with necessary gas-tight syringes, cannulaes, and septa. Stirring 
was achieved with oven-dried magnetic stir bars. Et2O, toluene, THF and CH2Cl2 were 
purified by passage through the Solv-Tek purification system employing activated Al2O3. 
Et3N was purified by passage over basic alumina and stored over KOH. Butyl lithium 
was purchased from Aldrich and titrated prior to use. Glycidol ether was acquired from 
Daiso Co. Ltd., Fine Chemical Department and used without further purification. Flash 
column chromatography was performed with Sorbent Technologies (30930M-25, Silica 
Gel 60A, 40-63 um). Thin layer chromatography was performed on silica gel 60F254 
plates (EM-5717, Merck). Visualization of TLC spots was achieved through the use of a 
UV lamp (254nm) and KMnO4 stain. Deuterated solvents were purchased from 
Cambridge Isotope laboratories. 1H, 13C NMR spectra were recorded in CDCl3 on a 
Bruker DRX-400 MHz spectrometer operating at 400 MHz and 100 MHz respectively or 
a Bruker Avance-500 MHz spectrometer operating at 500 MHz and 125 MHz 
respectively. Observed rotations at 589 nm were measured using AUTOPOL IV Model 
automatic polarimeter.  High-resolution mass spectrometry (HRMS) was recorded on a 
LCT Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH). 
 
General Procedure for the TBS protection of amino alcohols: To a RB flask with 
stirbar valanol was added (2.0 g,  17 mmol) in CH2Cl2 (34 mL, 0.5M). To the solution, 
triethylamine (4.7mL, 34 mmol), a catalytic amount of DMAP (159 mg, 1.7 mmol), and 
TMSCl (2.55 g, 17 mmol) was added and the reaction was stirred overnight. The reaction 
was extracted in water and EtOAc x3 and washed with brine to yield a pale yellow oil. 
 
General procedure for the one-pot synthesis of thiaoxaazepines: To a RB flask with 
stirbar (S)-1-(tert-butyldimethylsilyloxy)-3-methylbutan-2-amine was added (0.5425 g,  
2.5 mmol) in DCM (25 mL, 0.1M). The solution was cooled to 0 ºC and Et3N (1.045 mL, 
7.5 mmol) followed by 2-chloro-ethane sulfonyl chloride (0.263 mL, 2.5 mmol) was 
added. The reaction was allowed to stir at 0 ºC for 2 hours monitoring by TLC. Following 
completion of the reaction,  a 5 mL portion of the solution was placed in a screw-cap 
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Pyrex tube with stirbar. CsCO3 (488.8 mg, 1.5 mmol) and 4-methoxybenzyl bromide 
(138.5 mg,  0.75 mmol) was added. The reaction was heated to 80 ºC and allowed to stir 
overnight. Following completion of the reaction, the tube was removed from the bath and 
allowed to cool to room temperature. TBAF (0.5 mL, 1M in THF) was added and the 
reaction was allowed to stir for 20 min at rt. The reaction was evaporated under reduced 
pressure and columned in 5:1 hexanes: ethyl acetate to give to product as a colorless oil. 
 
General Procedure for the Intramolecular Baylis-Hillman Reaction: (The 
sulfonamide linchpin was prepared according to the previous procedure for the oxa-
Michael reaction) To a stirring solution of a TBS protected sulfonamide (1 equiv.) in 
trace amount of THF, 10 mol% HCl was added. The deprotected vinyl sulfonamide 
alcohol was extracted with CH2Cl2 dried, and filtered. The resulting alcohol was 
dissolved in CH2Cl2, Dess-Martin periodinate (2 equiv.) was added, and stirred for 2 
hours. The reaction was washed with NaHCO3 to remove the resultant solid acid, filtered, 
and extracted. DABCO (0.10 equiv) was added to the crude vinyl sulfonamide aldehyde 
in CH2Cl2. Stirring continues for 2-4 hours until the reaction was complete. 
 
3.2 Selected Library Data 
 
(S)-N-2-benzyl-3-phenyl-5,1,2-oxathiazepane-1,1-dioxide (11a) 
O
S
N
O O
 
[α]D20 -6.1 (c 0.50, CH2Cl2), colorless oil; FTIR (CH2Cl2): 3053, 2985, 1421, 1271, 894, 
761 cm-1; 1H-NMR (CDCl3, 400Hz): δ (ppm) 7.41 (aromatic CH, 4H), 7.33-7.25 
(aromatic CH, 4H), 4.85 (d, J = 15.3 Hz, 1H), 4.36 (dd, J = 5.5, 10.9 Hz, 1H), 4.21 (t,  J 
= 12.2, 1H), 4.13 (ddd, 1H), 4.13 (d, J = 5.5 1H), 4.06 (d, J = 15.4, 1H), 3.94 (td, J = 2.2, 
9.4 Hz, 1H), 3.42 (dt,  J = 2.1, 10.2 Hz, 1H), 2.93 (ddd, J = 4.5, 10.9, 14.8 Hz, 1H) 13C-
NMR (CDCl3, 100MHz): δ 138.07, 136.05, 129.70 (4), 128.43 (4), 127.08 (2), 76.17, 
 59 
60.19, 59.42,  58.77, 51.24 HRMS (ESI) m/z expected: 335.0992 m/z found: 353.1334 
(M+NH4) 
 
 (S)-N-2-(4-fluorobenzyl)-3-phenyl-5,1,2-oxathiazepane-1,1-dioxide (11d) 
O
S
N
F
O O
 
[α]D20 -21.4 (c 0.50, CH2Cl2), colorless oil; FTIR (CH2Cl2): 3053, 2985, 1421, 1253,  
894, 777 cm-1; 1H-NMR (CDCl3, 400Hz): δ (ppm) 7.42-7.28 (aromatic CH, 5H) 7.13 (d, 
J = 8.3 Hz, 1H), 4.73 (d, J = 15.4, 1H),  4.28 (dd, J = 5.4, 10.7 Hz, 1H),  4.19 (t,  J = 
12.1, 1H), 4.13 (ddd, 1H), 4.13 (d, J = 5.5 1H), 4.06 (d, J = 15.4, 1H), 3.96 (td, J = 2.2, 
12.2 Hz, 1H), 3.42 (dt,  J = 2.3, 14.2 Hz, 1H), 3.28 (ddd, J = 4.5, 11.5 15.2 Hz, 1H); 13C-
NMR (CDCl3, 100MHz): δ 137.07, 136.05, 132.42 (2),130.78 (2),  129.43 (2), 129.29, 
128.75 (2), 122.08, 76.77, 66.49, 63.74,  57.77, 52.84; HRMS (ESI) m/z expected: 
351.0696 m/z found: 410.1297 (M+NH4+CH3CN) 
 
(S)-N-2-(2-fluorobenzyl)-3-phenyl-5,1,2-oxathiazepane-1,1-dioxide (11e) 
O
S
N
O O
F
 
 
[α]D20 -13.4 (c 0.50, CH2Cl2), colorless oil; FTIR (CH2Cl2): 3060, 2985,  2304, 1421, 
1288, 1245, 896, 783 cm-1; 1H-NMR (CDCl3, 400Hz): δ (ppm) 7.45-7.25 (aromatic CH, 
5H) 7.08 (d, J = 7.6, 1H), 7.00 (m, 2H) 4.82 (d, J = 15.5, 1H), 4.40 (dd, J = 5.5, 11.6, 1H)  
4.26 (t, J = 12.1 Hz, 1H),  4.23-4.14 (m, 3H), 4.01 (td, J = 2.3, 12.3 Hz, 1H), 3.49 (dt, J = 
2.3, 14.2 Hz, 1H), 3.36 (ddd, 4.5, 11.3, 14.2 Hz, 1H); 13C-NMR (CDCl3, 100MHz): δ  
161.86, 138.64, 135.88, 130.86, 128.64 (2),  128.26, 127.75 (2), 124.29, 115.20, 114.32, 
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75.62, 66.37, 62.94, 57.75, 52.91; HRMS (ESI) m/z expected: 317.1086 m/z found: 
335.1459 (M+NH4) 
 
(6S)-5-[(3,4-dichlorophenyl)methyl]-6-phenyl-1,4,5-oxathiazepane 4,4-dioxide (11m) 
O
S
N
Cl
Cl
O O
 
[α]D20 -37 (c 0.50, CH2Cl2), colorless oil; FTIR (CH2Cl2): 3053, 2985, 2684, 2304, 1421, 
1265,  894, 777, 703 cm-1; 1H-NMR (CDCl3, 400Hz): δ (ppm) 7.33-7.20 (aromatic CH, 
6H) 7.04 (dd, J= 2.0, 8.2 Hz, 1H), 4.59 (d, J= 15.6 Hz, 1H) 7.10 (m, 1H) 4.82 (d, J = 
15.5, 1H),  4.40 (dd, J = 5.6, 10.9 Hz, 1H),  4.26 (t,  J = 12.9, 1H), 4.17 (m, 2H), 4.00 (td, 
J = 2.2, 11.2, 1H), 3.49 (dt, J = 2.4, 14.17, 1H), 3.36 (ddd, J = 4.5, 11.4,  30.1 Hz, 1H); 
13C-NMR (CDCl3, 100MHz): δ 138.51, 130.14 128.73 (2), 127.93 (2),  127.72 (2), 
124.26 115.50, 114.80, 76.76, 66.51, 63.72,  57.75, 52.86; HRMS (ESI) m/z expected: 
385.0306 m/z found: 444.0906 
 
N-2-(3-Fluorobenzyl)-3(S)-phenyl-5,1,2-oxathiazepine-1,1-dioxide (11n) 
O
S
N
O O
F
 
[α]D20 -17.0 (c 0.50, CH2Cl2), colorless oil; FTIR: 2956, 1454, 1335, 1140, 733 cm-1; 
1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.44-6.98 (m, 9H), 4.82 (d, J = 15.5 Hz, 1H), 4.23 
(dd, J = 10.8, 5.4 Hz, 1H), 4.19 (overlap, 3H), 4.00 (ddd, J = 13.5, 11.5, 2.3 Hz, 1H), 
3.49 (ddd, J =13.2, 2.4, 2.3 Hz, 1H), 3.37 (ddd, J = 11.4, 4.5, 2.7 Hz, 1H); 13C-NMR 
(CDCl3, 100 MHz): δ (ppm) 163.8, 161.8, 138.6, 136.0, 130.2, 128.7, 128.2, 127.4, 
124.2, 115.6, 75.7, 66.5, 63.7, 57.8, 52.9; HRMS (ESI) m/z calculated for C17H22N2 
FO3S 353.1335 (M+NH4)+, found 353.1134. 
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(6S)-5-[(4-bromophenyl)methyl]-6-butyl-1,4,5-oxathiazepane-4,4-dioxide (12r) 
O
S
N
Br
O
O
 
[α]D20 -47.4 (c 0.50, CH2Cl2), colorless oil; FTIR (CH2Cl2): 3053, 2985, 1421, 1336, 
1269, 1141, 1120, 703 cm-1; 1H-NMR (CDCl3, 400Hz): δ (ppm) 7.29 (m, 1H) 7.19 (m, 
2H), 4.73 (d, J = 15.4, 1H), 6.98 (td, J = 2.2, 6.9, 1H)  4.35 (q, J = 5.6, 12.7 Hz, 2H),  
4.19 (dt,  J = 1.8, 6.3, 1H), 4.06 (m, 1H), 3.92 (m, 1H), 3.83 (t, J = 11.3, 1H), 3.71 (m, 
1H), 3.34 (m, 1H), 1.35 (m, 2H), 1.00 (m, 4H), 0.67 (t, J = 6.6, 3H); 13C-NMR (CDCl3, 
100MHz): δ  161.83,140.14, 129.98,  124.02, 115.55,  114.77, 74.53 65.09, 55.87, 54.50, 
30.74, 28.47,  23.37, 13.78; HRMS (ESI) m/z expected: 361.0347 m/z found: 420.0900 
(M+NH4+CH3CN) 
 
N-2-(4-Bromobenzyl)-3(S)-isobutyl-5,1,2-oxathiazepine-1,1-dioxide (13r) 
O
N
S
OO
13r
Br
 
[α]D20 -35.0 (c 0.5, CH2Cl2), colorless oil; FTIR: 3053, 2985, 1421, 1261, 1155, 894, 
734 cm-1; 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.46-7.31 (m, 4H), 4.46 (d, J = 15.8 Hz, 
1H), 4.12 (d, J = 15.8 Hz, 1H), 4.07 (dd, J = 12.6, 6.4 Hz, 1H), 3.93 (overlap, 2H), 3.63 
(m, 1H), 3.38 (ddd, J = 14.4, 7.0, 4.7 Hz, 1H), 3.28 (ddd, J = 14.3, 6.3, 4.5 Hz, 1H), 1.45 
(m, 1H), 1.33 (m, 1H), 078 (m, 1H), 0.69 (d, J = 6.7 Hz, 3H), 0.47 (t, J = 7.4 Hz, 3H); 
13C-NMR (CDCl3, 100 MHz): δ (ppm) 136.5, 31.8, 130.5, 121.7, 73.8, 68.2, 61.8, 54.3, 
50.8, 36.4, 27.5, 15.4, 10.1; HRMS (ESI) m/z calculated for C15H26N2BrO3S 393.0848 
(M+NH4)+, found 393.0844. 
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Intermediates for and Final Compounds Baylis-Hillman-derived Sultams. 
 
N-benzyl-vinylsulfonamide 7c 
N
H
S
OO
 
1H-NMR (CDCl3, 400Hz): δ (ppm) 7.30 (s, 5H), 6.51 (dd, J= 6.8, 10.4, 1H), 6.27 (d,  J= 
10.4, 1H), 5.90 (d,  J= 10.0, 1H),  4.64 (s, 1H), 4.30 (d, J = 6.4, 2H) 
 
N-(tert-butyl)-vinylsulfonamide 7e 
N
H
S
OO
 
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.58 (dd,  J = 10.0, 16.8, 1H), 6.21 (d,  J = 16.4, 1H), 
5.89 (d,  J = 9.6, 1H), 4.23 (s, 1H), 1.39 (s, 9H) 
 
N-Allyl-N-isopropyl-vinylsulfonamide 8a 
N
S
O
O
 
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.42 (dd,  J = 10.0, 16.1, 1H), 6.18 (d,  J = 16.4, 1H), 
5.86 (d,  J = 9.6, 1H), 5.27 (dd,  J = 17.4, 1H), 5.20 (dd,  J = 10.4, 1H), 4.02 (m, 1H),  
3.81 (dd, J=0.80, 6.0, 2H), 1.18 (d, J=6.8, 6H) 
 
N-Allyl-N-benzyl-vinylsulfonamide 8c 
N
S
O
O
 
1H-NMR (CDCl3, 400Hz): δ (ppm) 7.32 (s, 5H), 6.42 (dd, J= 6.8, 10.4, 1H), 6.24 (d,  J= 
10.4, 1H), 5.90 (d,  J= 10.0, 1H),  5.74 (m, 1H), 5.20 (dd, J=17.4, 17.4, 2H) 4.73 (s, 2H), 
3.72 (d, J = 6.8, 2H), 
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N-isobutyl-N-(2-oxoethyl)ethenesulfonamide 9a 
N
S
O
O
O  
1H-NMR (CDCl3, 400Hz): δ (ppm) 9.60 (s, 1H), 6.58 (dd,  J = 9.6, 16.4, 1H), 6.25 (dd,  J 
= 0.80, 10.0, 1H), 5.95 (dd,  J = 0.40, 10.8, 1H), 4.10 (m, J = 7.2, 7.2, 7.2, 1H),  3.18 (s, 
1H), 1.41 (d, J = 6.8, 6H) 
 
N-(tert-butyl)-N-(2-oxoethyl)ethenesulfonamide 9e 
N
S
O
O
O  
1H-NMR (CDCl3, 400Hz): δ (ppm) 9.57 (s, 1H), 6.63 (dd,  J = 10.0, 16.8, 1H), 6.27 (dd,  
J = 0.80, 16.4, 1H), 5.86 (dd,  J = 0.40, 9.6, 1H), 4.02 (s, 1H),  1.36 (s, 9H) 
 
Methyl-2-(N-(2-oxoethyl)vinylsulfonamido)acetate 9g 
N
S
O
O
O
O
O
 
1H-NMR (CDCl3, 400Hz): δ (ppm) 9.64 (s, 1H), 6.55 (dd,  J = 6.4, 16.4, 1H), 6.26 (d, J 
= 16.4, 1H), 6.00 (d,  J = 9.6, 1H), 4.11 (s, 2H), 4.09 (s, 2H), 3.74 (s, 3H) 
 
2-Isopropyl-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10a 
N
S
OO
HO  
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.20 (s, 1H), 5.95 (s, 1H), 4.94 (s, 1H), 3.50 (dd),  
3.10 (ddd, 1H), 2.85 (s, 1H), 1.25 (m, 6H) 13C-NMR (CDCl3, 100 MHz): δ (ppm) 148.1, 
118.1, 65.2, 50.0, 45.2, 21.3 
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4-Hydroxy-2-(4-methoxyphenyl)-5-methyleneisothiazolidine 1,1-dioxide 10b 
N
S
OO
HO
O
 
1H-NMR (CDCl3, 400Hz): δ (ppm) 7.21 (d, J = 8.6, 2H), 6.89 (d, J = 8.6, 2H), 6.20 (s, 
1H), 5.95 (s, 1H),  4.75 (s, 1H), 3.78 (s, 3H), 3.31 (dd, 6.8, 10.2, 1H), 3.22 (s, 1H), 2.51 
(dd,  J = 5.0, 10.2, 1H) 13C-NMR (CDCl3, 100 MHz): δ (ppm) 159.7, 148.4, 130.0, 
119.4, 113.1, 64.9, 55.3, 52.9 
 
2-Benzyl-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10c 
N
S
OO
HO  
1H-NMR (CDCl3, 400Hz): δ (ppm) 7.30 (s, 5H), 6.22 (s, 1H), 5.97 (s, 1H), 4.78 (s, 1H), 
4.16 (s, 2H), 3.34 (dd, J = 6.7, 10.1, 1H), 2.96 (dd,  J = 4.9, 10.2, 1H) 13C-NMR (CDCl3, 
100 MHz): δ (ppm) 148.1, 134.6, 128.9, 119.2, 65.1,  52.0, 47.4 
 
2-Cyclohexyl-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10d 
N
S
OO
HO  
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.16 (s, 1H), 5.89 (s, 1H), 4.81 (s, 1H), 4.78 (s, 1H), 
3.84(q, 2H), 3.12 (dd, J = 6.7, 10.1, 1H), 2.77 (dd,  J = 4.9, 10.2, 1H) 13C-NMR (CDCl3, 
100 MHz): δ (ppm) 148.8, 118.0, 77.3, 65.5, 53.0, 48.4, 31.1, 25.4 
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2-(tert-Butyl)-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10e 
N
S
OO
HO  
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.11 (s, 1H), 5.85 (s, 1H), 4.80 (s, 1H), 3.59 (dd, J = 
6.4, 10.0, 1H),  3.18 (dd, J = 5.2, 5.2, 1H), 1.41 (s, 9H) 13C-NMR (CDCl3, 100 MHz): δ 
(ppm) 149.9, 117.6, 77.2, 64.5, 49.9, 28.0 
 
4-Hydroxy-5-methylene-2-(prop-2-yn-1-yl)isothiazolidine 1,1-dioxide 10f 
N
S
OO
HO  
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.22 (s, 1H), 6.01 (s, 1H), 4.91 (s, 1H), 3.93 (s, 1H), 
3.66 (q, 2H), 3.46 (dd, J = 6.7, 10.1, 1H), 3.26 (dd,  J = 4.9, 10.2, 1H) 2.99 2.37 2.16 13C-
NMR (CDCl3, 100 MHz): δ (ppm) 146.8, 118.4, 77.5, 75.4, 73.1, 54.3, 33.0 
 
Methyl 2-(4-hydroxy-5-methylene-1,1-dioxidoisothiazolidin-2-yl)acetate 10g 
N
S
OO
HO
O
O  
1H-NMR (CDCl3, 400Hz): δ (ppm) 6.12 (s, 1H), 5.96 (s, 1H), 4.78 (s, 1H), 3.55 (s, 1H), 
3.27 (dd, 1H), 3.05 (dd, J = 6.7, 10.1, 1H) 13C-NMR (CDCl3, 100 MHz): δ (ppm) 169.5, 
147.9, 119.2, 69.6, 54.1, 52.5, 43.8 
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Appendix: 
NMR Spectra 
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(S)-N-2-benzyl-3-phenyl-5,1,2-oxathiazepane-1,1-dioxide (11a) 
O
S N
O O
1H in CDCl3
 
O
S N
O O
13C in CDCl3
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O
S N
O O
DEPT in CDCl3
 
 
(S)-N-2-(4-fluorobenzyl)-3-phenyl-5,1,2-oxathiazepane-1,1-dioxide (11d) 
O
S N
O O
1H in CDCl3
F
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O
NS
OO
F
13C in CDCl3
 
O
NS
OO
F
DEPT in CDCl3
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(S)-N-2-(2-fluorobenzyl)-3-phenyl-5,1,2-oxathiazepane-1,1-dioxide (11e) 
O
S N
O O
1H in CDCl3
F
 
O
NS
OO
13C in CDCl3
F
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(6S)-5-[(3,4-dichlorophenyl)methyl]-6-phenyl-1,4,5-oxathiazepane 4,4-dioxide (11m) 
O
S N
O O
1H in CDCl3
Cl
Cl
 
O
S N
O O
13C in CDCl3
Cl
Cl
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O
S N
O O
DEPT in CDCl3
Cl
Cl
 
N-2-(3-Fluorobenzyl)-3(S)-phenyl-5,1,2-oxathiazepine-1,1-dioxide (11n) 
O
S N
O O
1H in CDCl3
F
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O
S N
O O
13C in CDCl3
F
 
O
S N
O O
DEPT in CDCl3
F
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(6S)-5-[(4-bromophenyl)methyl]-6-butyl-1,4,5-oxathiazepane-4,4-dioxide (12r) 
O
S N
O O
1H in CDCl3
Br
 
O
S N
O O
13C in CDCl3
Br
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O
S N
O O
DEPT in CDCl3
Br
 
 
N-2-(4-Bromobenzyl)-3(S)-isobutyl-5,1,2-oxathiazepine-1,1-dioxide (13r) 
O
S N
O O
1H in CDCl3
Br
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O
S N
O O
13C in CDCl3
Br
 
O
S N
O O
DEPT in CDCl3
Br
 
 
 
 77 
Selected Intermediates for Baylis-Hillman-derived Sultams. 
N-benzyl-vinylsulfonamide 7c 
1H in CDCl3
N
H
S
OO
 
O
S N
O O F
DEPT in CDCl3
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N-(tert-butyl)-vinylsulfonamide 7e 
1H in CDCl3
N
H
S
OO
 
N-benzyl-vinylsulfonamide 7c 
1H in CDCl3
N
H
S
OO
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N-Allyl-N-isopropyl-vinylsulfonamide 8a 
1H in CDCl3
NS
OO
 
N-Allyl-N-benzyl-vinylsulfonamide 8c 
1H in CDCl3
NS
OO
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N-isopropyl-N-(2-oxoethyl)ethenesulfonamide 9a 
1H in CDCl3
NS
OO
O
 
N-isopropyl-N-(tert-butyl)ethenesulfonamide 9e 
1H in CDCl3
NS
OO
O
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Methyl-2-(N-(2-oxoethyl)vinylsulfonamido)acetate 9g 
1H in CDCl3
NS
OO
O
O
O
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Final Compounds Baylis-Hillman-derived Sultams. 
2-isopropyl-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10a 
1H in CDCl3
N
S
OO
HO
 
13C in CDCl3
N
S
OO
HO
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4-hydroxy-2-(4-methoxyphenyl)-5-methyleneisothiazolidine 1,1-dioxide 10b 
1H in CDCl3
N
S
OO
HO
O
 
13C in CDCl3
N
S
OO
HO
O
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2-benzyl-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10c 
1H in CDCl3
N
S
OO
HO
 
13C in CDCl3
N
S
OO
HO
 
 
2-Cyclohexyl-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10d 
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1H in CDCl3
N
S
OO
HO
 
13C in CDCl3
N
S
OO
HO
 
 
 
2-(tert-butyl)-4-hydroxy-5-methyleneisothiazolidine 1,1-dioxide 10e 
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1H in CDCl3
N
S
OO
HO
 
 
13C in CDCl3
N
S
OO
HO
 
 
 
4-Hydroxy-5-methylene-2-(prop-2-yn-1-yl)isothiazolidine 1,1-dioxide 10f 
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1H in CDCl3
N
S
OO
HO
 
 
13C in CDCl3
N
S
OO
HO
 
 
Methyl 2-(4-hydroxy-5-methylene-1,1-dioxidoisothiazolidin-2-yl)acetate 10g 
 88 
1H in CDCl3
N
S
OO
HO
O
O
 
13C in CDCl3
N
S
OO
HO
O
O
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